$Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy$

Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy

Multiple myeloma (MM) and primary systemic light chain amyloidosis (AL) are both chronic plasma cell dyscrasias with different clinical expression but limited treatment options for relapsed refractory disease. We report the effect of the addition of clarithromycin on 31 MM and 17 AL with relapsed or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2017-02, Vol.92 (2), p.131-135
Hauptverfasser:	Shaulov, Adir, Ganzel, Chezi, Benyamini, Noam, Barshay, Yossef, Goldschmidt, Neta, Lavie, David, Libster, Diana, Gural, Alex, Avni, Batia, Gatt, Moshe E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Amyloidosis - complications Amyloidosis - drug therapy Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clarithromycin - administration & dosage Clarithromycin - pharmacology Disease Progression Fatigue - chemically induced Female Hematology Humans Immunoglobulin Light Chains Immunoglobulin Light-chain Amyloidosis Infection - chemically induced Male Middle Aged Multiple Myeloma - complications Multiple Myeloma - drug therapy Protein Synthesis Inhibitors - therapeutic use Recurrence Salvage Therapy - adverse effects Salvage Therapy - methods Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!